The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.